Related Experiment Videos
Management of hepatitis C: current and future perspectives
1Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. HoofnagleJ@hq.niddk.nih.gov
Journal of Hepatology
|January 6, 2000
Summary
Updated hepatitis C management guidelines recommend alpha interferon plus ribavirin therapy. Optimal treatment duration varies by viral genotype, with shorter courses for genotypes 2 and 3.
Area of Science:
- Hepatology and Viral Gastroenterology
- Clinical Medicine
- Evidence-Based Medicine
Background:
- Chronic hepatitis C is a leading cause of liver disease, cirrhosis, and liver cancer.
- National Institutes of Health (NIH) guidelines for hepatitis C management were established in 1997.
- Rapid advancements necessitate updating these evidence-based recommendations.
Purpose of the Study:
- To review and update management recommendations for chronic hepatitis C.
- To evaluate the clinical utility of hepatitis C virus (HCV) genotyping.
- To determine optimal therapeutic regimens for chronic hepatitis C.
Main Methods:
- Analysis of two large multicenter, prospective controlled trials.
- Evaluation of sustained virologic response rates with different treatment regimens.
- Assessment of treatment duration based on HCV genotype.
Main Results:
- Combination therapy with alpha interferon and ribavirin yields higher sustained virologic responses than interferon alone.
- Optimal therapy duration is 24 weeks for genotypes 2 and 3, and 48 weeks for genotype 1.
- Treatment can be discontinued at 24 weeks if HCV RNA remains detectable.
Conclusions:
- HCV genotyping is clinically useful for guiding therapy duration.
- Alpha interferon and ribavirin combination therapy is superior to interferon monotherapy.
- Further research is needed for improved disease staging, progression prediction, and novel therapies.